Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and co-inhibitory pathways to enhance antitumor responses.
At the ongoing International Society for Stem Cell Research meeting, Chinese researchers reported they demonstrated that SPT6 homolog, histone chaperone and transcription elongation factor (SPT6) promotes epidermal stem/progenitor cells differentiation by facilitating transcriptional elongation, but its role in vivo in skin homeostasis is not well defined.
IgA nephropathy is a progressive kidney disease characterized by the deposition of immune complexes containing IgA, where a proliferation-inducing ligand (APRIL) drives the production of pathogenic IgA. Jade Biosciences Inc. has developed a novel APRIL-binding therapeutic, JADE-101, for the treatment of IgA nephropathy.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the need for innovative therapeutic approaches. CD97 is a cell surface protein with broad, increased expression on AML cells compared to normal blood stem and progenitor cells. Moreover, CD97 overexpression in AML patients has been associated with poor survival, thus emerging as a potential therapeutic target.
Researchers at Korea Research Institute of Chemical Technology and University of Ulsan have described UBA6-specific E2 conjugating enzyme 1 (USE1) inhibitors reported to be useful for the treatment of cancer.
Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, interstitial lung diseases, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and primary biliary cholangitis.
Scientists at Helmholtz Zentrum für Infektionsforschung GmbH, Rijksuniversiteit Groningen and Université de Lausanne have synthesized energy-coupling factor (ECF) transporter (bacterial) inhibitors reported to be useful for the treatment of enterococcal and streptococcal infections.
Maplight Therapeutics Inc. has disclosed G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of neurological and psychiatric disorders.
Embryonal tumor with multilayered rosettes (ETMR) is a rare but aggressive brain cancer that affects very young children, typically under the age of 3 years. Survival rates for ETMR patients remain low, with a median survival of just over a year and only about 20% of patients living beyond 5 years.
RSS
